- Available
Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study
This programme offers continued access to an investigational drug, BIA 28-6156, for people with a specific type of Parkinson's disease (related to the GBA1 gene) who have already completed a previous study. It provides the medicine free of charge on compassionate grounds.
For: Parkinson DiseaseUnited States · Italy · Portugal - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson’s Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene
This study is looking into a new medicine, BIA 28-6156, for people with Parkinson's disease linked to a specific gene change (GBA1). It wants to see if the medicine can slow down how the disease affects everyday activities and movement.
For: Parkinson’s DiseaseGermany · Netherlands · Sweden